(1S)-hexadecyl-2-(4'-carboxybutyl)-glycero-3-phosphocholine | 936227-77-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: (1S)-hexadecyl-2-(4'-carboxybutyl)-glycero-3-phosphocholine
• 英文别名: 1-S-hexadecyl-2-(4-carboxy)butyl-sn-glycero-3-phosphocholine；[(2S)-2-(4-carboxybutoxy)-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 936227-77-9
• 化学式: C₂₉H₆₀NO₈P
• 分子量: 581.771
• InChiKey: JGGNOCUEWOGWPL-NDEPHWFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  39
• 可旋转键数：
  30
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-S-hexadecyl-2-(4-methylcarboxy)butyl-sn-glycero-3-phosphocholine 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成 (1S)-hexadecyl-2-(4'-carboxybutyl)-glycero-3-phosphocholine
  参考文献：
  名称：

  [EN] OXIDIZED LIPID COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS LIPIDIQUES OXYDÉS ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2010052718A9

文献信息

• Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
  申请人：Harats Dror

  公开号：US20100048515A1

  公开（公告）日：2010-02-25

  Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.

  提供了一种新型合成的氧化脂质以及利用氧化脂质用于治疗和预防与内源性氧化脂质相关的炎症的方法。
• OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS
  申请人：Vascular Biogenics Ltd.

  公开号：EP1626728B1

  公开（公告）日：2013-07-10
• COMBINED TREATMENT UTILIZING VB-201
  申请人：Vascular Biogenics Ltd.

  公开号：EP2521569B1

  公开（公告）日：2017-11-01
• TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
  申请人：Vascular Biogenics Ltd.

  公开号：EP2791101B1

  公开（公告）日：2019-09-18
• Combined Treatment Utilizing VB-201
  申请人：Cohen Yael

  公开号：US20120329758A1

  公开（公告）日：2012-12-27

  Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.